Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Gemcitabine on Intracranial Erlich Tumor and its Determinants.
Stukov AN, Bespalov VG, Alexandrov VA, Semenov AL, Kireeva GS, Semiglazova TY, Filatova LV, Baranenko DA. Stukov AN, et al. Among authors: filatova lv. Drug Res (Stuttg). 2020 Feb;70(2-03):86-90. doi: 10.1055/a-0824-6325. Epub 2019 Sep 25. Drug Res (Stuttg). 2020. PMID: 31556073
[Therapeutic activity of gemcitabine in intracranial tumors].
Stukov AN, Filatova LV, Latipova DKh, Bespalov VG, Belyaeva OA, Kireeva GS, Vasilieva IN, Alexandrov VA, Maidin MA, Semenov AL, Vershinina SF, Markochev AB, Abduloeva NKh, Chubenko VA, Semiglazova TY. Stukov AN, et al. Among authors: filatova lv. Vopr Onkol. 2015;61(2):274-9. Vopr Onkol. 2015. PMID: 26087611 Russian.
Enchancement of Toremifene Anti-Tumor Action by Metformin and Unusual Side Effect of Toremifene in Male Transgenic Mice with HER2-Positive Breast Tumor.
Stukov AN, Osipov MA, Semiglazova TY, Filatova LV, Alexandrov VA, Bespalov VG, Semenov AL, Tyndyk ML, Yurova MN, Panchenko AV, Baranenko DA. Stukov AN, et al. Among authors: filatova lv. Drug Res (Stuttg). 2019 Dec;69(12):683-687. doi: 10.1055/a-0892-4118. Epub 2019 Sep 24. Drug Res (Stuttg). 2019. PMID: 31550733
Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemotherapy.
Gershanovich ML, Filatova LV, Ketlinsky SA, Simbirtsev AS. Gershanovich ML, et al. Among authors: filatova lv. Eur Cytokine Netw. 2001 Oct-Dec;12(4):664-70. Eur Cytokine Netw. 2001. PMID: 11781194 Free article. Clinical Trial.
Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. II. Phase II study of the protective effect of recombinant human interleukin-1 beta on myelodepression induced by chemotherapy in cancer patients.
Gershanovich ML, Filatova LV, Ketlinsky SA, Simbirtsev AS. Gershanovich ML, et al. Among authors: filatova lv. Eur Cytokine Netw. 2001 Oct-Dec;12(4):671-5. Eur Cytokine Netw. 2001. PMID: 11781195 Free article. Clinical Trial.
50 results